caption
stringlengths 0
3.92k
| molecule
stringlengths 1
914
| properties
listlengths 1
113
| additional_data
dict |
|---|---|---|---|
The molecule is a stabilizing mitochondrial structure, proton trap for oxidative phosphorylation, apoptosis, stabilizing cytochrome oxidase that impacts diabetic heart disease. The molecule is a cholesterol translocation that impacts aging, non-alcoholic fatty liver disease, barth syndrome, and tangier disease.
|
CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCC(=O)OC[C@H](COP(=O)(O)OC[C@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCC/C=C\CCCCCC)OC(=O)CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CC)OC(=O)CCCCCCCCCCCCC
|
[
"Stabilizing mitochondrial structure",
"Proton trap for oxidative phosphorylation",
"Apoptosis",
"Diabetic heart disease",
"Stabilizing cytochrome oxidase",
"Aging",
"Non-alcoholic fatty liver disease",
"Barth syndrome",
"Tangier disease",
"Cholesterol translocation"
] |
{
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
}
|
The molecule is a stabilizing cytochrome oxidase, proton trap for oxidative phosphorylation, cholesterol translocation that impacts non-alcoholic fatty liver disease and tangier disease. The molecule is a stabilizing mitochondrial structure and a apoptosis that impacts diabetic heart disease, barth syndrome, and aging.
|
CCCCCCCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCC(C)CC)OC(=O)CCCCCCCCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCCCCCCCCC
|
[
"Stabilizing cytochrome oxidase",
"Non-alcoholic fatty liver disease",
"Proton trap for oxidative phosphorylation",
"Tangier disease",
"Cholesterol translocation",
"Diabetic heart disease",
"Barth syndrome",
"Stabilizing mitochondrial structure",
"Apoptosis",
"Aging"
] |
{
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
}
|
It impacts copd treatment.
|
CCC1CNCc2cccc(F)c2O1.Cl
|
[
"COPD treatment"
] |
{
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
}
|
The molecule is a anti neoplastic and belongs to the anti body class of molecules, with the characteristic of being anti body drug conjugate.
|
CCC(C)C(C(CC(=O)N1CCCC1C(OC)C(C)C(=O)NC(CN)Cc1ccc(N)cc1)OC)N(C)C(=O)CNC(=O)C(C(C)C)N(C)C
|
[
"anti neoplastic",
"anti body",
"anti body drug conjugate"
] |
{
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
}
|
The molecule is a cholesterol translocation, stabilizing cytochrome oxidase, apoptosis that impacts aging and diabetic heart disease. The molecule is a stabilizing mitochondrial structure and a proton trap for oxidative phosphorylation that impacts tangier disease, barth syndrome, and non-alcoholic fatty liver disease.
|
CCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCC)OC(=O)CCCCCCCCCC(C)C)OC(=O)CCCCCCCCCCCCCC(C)C
|
[
"Aging",
"Diabetic heart disease",
"Cholesterol translocation",
"Stabilizing cytochrome oxidase",
"Apoptosis",
"Stabilizing mitochondrial structure",
"Tangier disease",
"Barth syndrome",
"Proton trap for oxidative phosphorylation",
"Non-alcoholic fatty liver disease"
] |
{
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
}
|
It belongs to the electroluminescent class of molecules.
|
c1ccc(-c2ccc(-c3cc(-c4ccccc4)cc(-c4nc(-c5ccccc5)nc(-c5ccc6c7ccccc7c7ccccc7c6c5)n4)c3)cc2)cc1
|
[
"electroluminescent"
] |
{
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
}
|
The molecule is a protein kinase inhibitor.
|
N#Cc1c(-c2ccccc2-c2cc3ccccc3s2)[nH]c(=S)[nH]c1=O
|
[
"protein kinase inhibitor"
] |
{
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
}
|
It impacts insulin resistance, neurodegenerative disease, and diabetes mellitus.
|
CCC/C=C\CCCCCCCC/C=C/[C@@H](O)[C@H](CO)NC(=O)CCCC(O)/C=C/C=C/C/C=C/CCCCCCCC
|
[
"Insulin resistance",
"Neurodegenerative disease",
"Diabetes mellitus"
] |
{
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
}
|
The molecule is a surfactant, a proton trap for oxidative phosphorylation, and a membrane stabilizer, and it impacts diabetic heart disease. The molecule is a energy source, cholesterol translocation, emulsifier that impacts tangier disease and barth syndrome. The molecule is a nutritional supplement and a food additive, it impacts non-alcoholic fatty liver disease, and is smooth. The molecule is a stabilizing cytochrome oxidase, stabilizing mitochondrial structure, energy storage, apoptosis that impacts aging.
|
CC(C)CCCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCC(C)C)OC(=O)CCCCCCCCCCC(C)C)OC(=O)CCCCCCCCCC(C)C
|
[
"surfactant",
"Proton trap for oxidative phosphorylation",
"Diabetic heart disease",
"Membrane stabilizer",
"Tangier disease",
"Energy source",
"Cholesterol translocation",
"Emulsifier",
"Barth syndrome",
"Nutritional supplement",
"Smooth",
"Non-alcoholic fatty liver disease",
"food additive",
"Stabilizing cytochrome oxidase",
"Stabilizing mitochondrial structure",
"Energy storage",
"Aging",
"Apoptosis"
] |
{
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
}
|
The molecule is a flavoring agent, a nutrient, animal, cocoa, and castoreum. The molecule is mango, honey, and balsam; further, it is sweet, jasmine, and chocolate.
|
Cc1c(Cl)c(O)cc(O)c1C(=O)OC1CC2(C)C3CC(C)(C)CC3C=C(C=O)C12O
|
[
"Flavoring agent",
"nutrient",
"animal",
"cocoa",
"castoreum",
"mango",
"honey",
"balsam",
"sweet",
"jasmine",
"chocolate"
] |
{
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
}
|
The molecule is a inflammatory disease treatment and belongs to the integrin antagonist class of molecules.
|
CCC(CC)Nc1cc(F)c(C(=O)NC(Cc2ccc(-c3c(C(F)(F)F)cc(C)n(C)c3=O)c3ncccc23)C(=O)O)c(F)c1
|
[
"inflammatory disease treatment",
"integrin antagonist"
] |
{
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
}
|
The molecule is a stabilizing mitochondrial structure, proton trap for oxidative phosphorylation, cholesterol translocation, apoptosis that impacts barth syndrome. The molecule is a stabilizing cytochrome oxidase that impacts tangier disease, aging, non-alcoholic fatty liver disease, and diabetic heart disease.
|
CCCCCCCC(=O)OC[C@H](COP(=O)(O)OC[C@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCCCC(C)CC)OC(=O)CCCCCCCCCCCCCCCCCCC(C)C)OC(=O)CCCCCCCCCCC(C)CC
|
[
"Stabilizing mitochondrial structure",
"Proton trap for oxidative phosphorylation",
"Cholesterol translocation",
"Apoptosis",
"Barth syndrome",
"Tangier disease",
"Aging",
"Non-alcoholic fatty liver disease",
"Diabetic heart disease",
"Stabilizing cytochrome oxidase"
] |
{
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
}
|
The molecule is a pde1 inhibitor and belongs to the neurodegenerative treatment class of molecules, with the characteristic of being psychiatric treatment.
|
O=c1c2cnc(I)n2cc(Cc2ccc(Br)cc2)n1I
|
[
"psychiatric treatment",
"pde1 inhibitor",
"neurodegenerative treatment"
] |
{
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
}
|
The molecule is a energy storage that impacts pancreatitis, metabolic syndrome, atherosclerosis, obesity, and cardiovascular disease. The molecule is a energy source and membrane stabilizer with an effect on cancer. The molecule is a inflammatory, a nutrient, and a fat storage, and it impacts thyroxine treatment.
|
CCCCCCCCCCCCCC(=O)OC[C@H](COC(=O)CCCCCCCCCCCCCCCCCCCCC(C)CC)OC(=O)CCCCCCCCCCCCCCCCCCCCC(C)CC
|
[
"Pancreatitis",
"Metabolic syndrome",
"Energy storage",
"Atherosclerosis",
"Obesity",
"Cardiovascular disease",
"Energy source",
"Cancer",
"Membrane stabilizer",
"inflammatory",
"Thyroxine treatment",
"nutrient",
"Fat storage"
] |
{
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
}
|
The molecule is a fat storage, energy source, membrane stabilizer that impacts metabolic syndrome, atherosclerosis, and obesity. The molecule is a inflammatory and nutrient, and it impacts cardiovascular disease. The molecule is a energy storage belonging to the thyroxine treatment class, known to affect cancer and impact pancreatitis.
|
CCCCCCCCCCCCCCC(=O)OC[C@H](COC(=O)CCCCCCCCCCC(C)CC)OC(=O)CCCCCCCCC
|
[
"Fat storage",
"Energy source",
"Metabolic syndrome",
"Membrane stabilizer",
"Atherosclerosis",
"Obesity",
"inflammatory",
"nutrient",
"Cardiovascular disease",
"Cancer",
"Thyroxine treatment",
"Energy storage",
"Pancreatitis"
] |
{
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
}
|
The molecule is photosensitive.
|
C=CC(=O)O.O=C1NC(=O)C2CCC=CC12
|
[
"photosensitive"
] |
{
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
}
|
The molecule is a apoptosis, stabilizing cytochrome oxidase, cholesterol translocation that impacts non-alcoholic fatty liver disease and tangier disease. The molecule is a stabilizing mitochondrial structure and a proton trap for oxidative phosphorylation that impacts aging, diabetic heart disease, and barth syndrome.
|
CC/C=C\C/C=C\C/C=C\C/C=C\CCCCC(=O)OC[C@H](COP(=O)(O)OC[C@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCCCC
|
[
"Apoptosis",
"Non-alcoholic fatty liver disease",
"Stabilizing cytochrome oxidase",
"Tangier disease",
"Cholesterol translocation",
"Stabilizing mitochondrial structure",
"Aging",
"Diabetic heart disease",
"Proton trap for oxidative phosphorylation",
"Barth syndrome"
] |
{
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
}
|
The molecule is a stabilizing mitochondrial structure, stabilizing cytochrome oxidase, apoptosis that impacts tangier disease and diabetic heart disease. The molecule is a proton trap for oxidative phosphorylation and a cholesterol translocation that impacts barth syndrome, aging, and non-alcoholic fatty liver disease.
|
CCCCC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCC(=O)OC[C@H](COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCC/C=C\C/C=C\C/C=C\C/C=C\CCCCC)OC(=O)CCCCCCCCCCCCCCCCC
|
[
"Tangier disease",
"Stabilizing mitochondrial structure",
"Stabilizing cytochrome oxidase",
"Apoptosis",
"Diabetic heart disease",
"Proton trap for oxidative phosphorylation",
"Barth syndrome",
"Cholesterol translocation",
"Aging",
"Non-alcoholic fatty liver disease"
] |
{
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
}
|
The molecule is both a osmolyte and a signalling molecule.
|
CC(C)(CO)[C@@H](O)C(=O)NCCC(=O)NCCSSCCNC(=O)CCNC(=O)[C@H](O)C(C)(C)CO
|
[
"osmolyte",
"signalling molecule"
] |
{
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
}
|
The molecule is a stabilizing cytochrome oxidase and a cholesterol translocation that impacts tangier disease, diabetic heart disease, and barth syndrome. The molecule is a stabilizing mitochondrial structure, proton trap for oxidative phosphorylation, apoptosis that impacts non-alcoholic fatty liver disease and aging.
|
CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)OC[C@H](COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCCC)OC(=O)CCCCCCC/C=C\CCCCCCCC)OC(=O)CCCCCCC/C=C\CCCCCC
|
[
"Tangier disease",
"Stabilizing cytochrome oxidase",
"Diabetic heart disease",
"Cholesterol translocation",
"Barth syndrome",
"Stabilizing mitochondrial structure",
"Non-alcoholic fatty liver disease",
"Proton trap for oxidative phosphorylation",
"Apoptosis",
"Aging"
] |
{
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
}
|
The molecule is anti viral.
|
CC(C)=CCCC(C)=CCO.COc1cc(C=CC(=O)O)ccc1O
|
[
"anti viral"
] |
{
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
}
|
The molecule is a energy storage and a nutrient that impacts metabolic syndrome, atherosclerosis, cardiovascular disease, and cancer. The molecule is a inflammatory and thyroxine treatment, and it impacts obesity. The molecule is a fat storage, a membrane stabilizer, and a energy source, and it impacts pancreatitis.
|
CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCC)OC(=O)CCCCCCCCCCCCCCCCC
|
[
"Metabolic syndrome",
"Energy storage",
"Atherosclerosis",
"nutrient",
"Cardiovascular disease",
"Cancer",
"Obesity",
"Thyroxine treatment",
"inflammatory",
"Fat storage",
"Membrane stabilizer",
"Energy source",
"Pancreatitis"
] |
{
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
}
|
The molecule is a membrane stabilizer and energy source, affecting cancer, and impacting cardiovascular disease, metabolic syndrome, and pancreatitis. The molecule is a fat storage that impacts both obesity and atherosclerosis. The molecule is a energy storage, a nutrient, a inflammatory, and thyroxine treatment.
|
CCCCCCCCCCCCCC(=O)O[C@@H](COC(=O)CCCCCCCCCCCCCCCCCCCCC(C)C)COC(=O)CCCCCCCCCCC(C)C
|
[
"Cardiovascular disease",
"Membrane stabilizer",
"Metabolic syndrome",
"Cancer",
"Energy source",
"Pancreatitis",
"Obesity",
"Atherosclerosis",
"Fat storage",
"Energy storage",
"nutrient",
"inflammatory",
"Thyroxine treatment"
] |
{
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
}
|
The molecule is a inflammatory, nutrient, energy source that impacts pancreatitis, cancer, and thyroxine treatment. The molecule is a fat storage that impacts both obesity and cardiovascular disease. The molecule is a energy storage and a membrane stabilizer, impacting both metabolic syndrome and atherosclerosis.
|
CCCCCCCCCCCCCCCCCCCC(=O)OC[C@H](COC(=O)CCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCC(C)C
|
[
"Pancreatitis",
"inflammatory",
"Cancer",
"Thyroxine treatment",
"nutrient",
"Energy source",
"Obesity",
"Cardiovascular disease",
"Fat storage",
"Energy storage",
"Metabolic syndrome",
"Membrane stabilizer",
"Atherosclerosis"
] |
{
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
}
|
The molecule is a food additive and a stabilizing mitochondrial structure, it impacts aging, and is smooth. The molecule is a stabilizing cytochrome oxidase, energy storage, energy source, emulsifier that impacts diabetic heart disease. The molecule is a cholesterol translocation and a membrane stabilizer, impacting both non-alcoholic fatty liver disease and barth syndrome. The molecule is a proton trap for oxidative phosphorylation, nutritional supplement, surfactant, apoptosis that impacts tangier disease.
|
CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCCCC(=O)OC[C@H](COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCC/C=C\CCCCCC)OC(=O)CCCCCCC/C=C\C/C=C\CCCCC)OC(=O)CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCCC
|
[
"Smooth",
"Aging",
"food additive",
"Stabilizing mitochondrial structure",
"Diabetic heart disease",
"Stabilizing cytochrome oxidase",
"Energy storage",
"Energy source",
"Emulsifier",
"Cholesterol translocation",
"Non-alcoholic fatty liver disease",
"Barth syndrome",
"Membrane stabilizer",
"Proton trap for oxidative phosphorylation",
"Nutritional supplement",
"surfactant",
"Tangier disease",
"Apoptosis"
] |
{
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
}
|
It belongs to the muscarinic receptor antagonist class of molecules.
|
O=C(Nc1ccccc1-c1ccccc1)OC1CCN(CCCCc2ccc(CCNCC(O)c3ccc(O)c4[nH]c(=O)ccc34)cc2)CC1
|
[
"muscarinic receptor antagonist"
] |
{
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
}
|
It belongs to the luminescent class of molecules.
|
C=CC=CC(=CC)N(c1ccccc1NC)C(C)c1cc(-c2nc(C=CC=C)c(C)n2CC=CC=CC)cc(-c2nc3ccccc3n2C2=CCC=CC=CC2)c1
|
[
"luminescent"
] |
{
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
}
|
The molecule is anti viral.
|
COCC1CC(c2nc3c(ccc4cc5c(cc43)OCc3cc(-c4cnc(C6(C(C)(C)C)CC(COC)CN6C(=O)O)[nH]4)ccc3-5)[nH]2)N(C(=O)OC(C)(C)C)C1
|
[
"anti viral"
] |
{
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
}
|
The molecule is a apoptosis and a stabilizing cytochrome oxidase that impacts tangier disease, non-alcoholic fatty liver disease, and barth syndrome. The molecule is a proton trap for oxidative phosphorylation, stabilizing mitochondrial structure, cholesterol translocation that impacts aging and diabetic heart disease.
|
CCCCCCCCCCCCCCCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCCCCCCC(C)C)COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCC)OC(=O)CCCCCCCCCCCCC(C)CC
|
[
"Apoptosis",
"Tangier disease",
"Stabilizing cytochrome oxidase",
"Non-alcoholic fatty liver disease",
"Barth syndrome",
"Proton trap for oxidative phosphorylation",
"Aging",
"Stabilizing mitochondrial structure",
"Diabetic heart disease",
"Cholesterol translocation"
] |
{
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
}
|
The molecule is a stabilizing mitochondrial structure and a cholesterol translocation that impacts aging, diabetic heart disease, and barth syndrome. The molecule is a proton trap for oxidative phosphorylation, apoptosis, stabilizing cytochrome oxidase that impacts non-alcoholic fatty liver disease and tangier disease.
|
CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCC(=O)O[C@H](COC(=O)CCCCCCC/C=C\CCCCCCCC)COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCC/C=C\C/C=C\C/C=C\CC
|
[
"Aging",
"Diabetic heart disease",
"Stabilizing mitochondrial structure",
"Barth syndrome",
"Cholesterol translocation",
"Proton trap for oxidative phosphorylation",
"Non-alcoholic fatty liver disease",
"Apoptosis",
"Stabilizing cytochrome oxidase",
"Tangier disease"
] |
{
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
}
|
The molecule is a cholesterol translocation and a apoptosis that impacts aging, barth syndrome, and non-alcoholic fatty liver disease. The molecule is a proton trap for oxidative phosphorylation, stabilizing cytochrome oxidase, stabilizing mitochondrial structure that impacts diabetic heart disease and tangier disease.
|
CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)OC[C@H](COP(=O)(O)OC[C@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCC/C=C\C/C=C\CCCCC)OC(=O)CCC/C=C\C/C=C\C/C=C\C/C=C\CCCCC)OC(=O)CCCCCCCCCCCCC
|
[
"Cholesterol translocation",
"Aging",
"Apoptosis",
"Barth syndrome",
"Non-alcoholic fatty liver disease",
"Proton trap for oxidative phosphorylation",
"Diabetic heart disease",
"Tangier disease",
"Stabilizing cytochrome oxidase",
"Stabilizing mitochondrial structure"
] |
{
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
}
|
The molecule is a cancer treatment.
|
CNCCN(Cc1ncccc1C(F)(F)F)C(=O)CNc1cccc2c1CCN(C(=O)NC1CCCCC1)C2
|
[
"cancer treatment"
] |
{
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
}
|
The molecule is a inflammatory disease treatment and a anti inflammatory, belonging to the psoriasis treatment class of molecules.
|
CCCCCCCCOc1cc(OCCCCCCCCOc2ccc(O)cc2)cc(C(=O)O)c1
|
[
"inflammatory disease treatment",
"psoriasis treatment",
"anti inflammatory"
] |
{
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
}
|
The molecule is a protein kinase inhibitor, a akt inhibitor, and cancer treatment.
|
COc1ccc(CC(N)C(=O)C(C)C)cc1
|
[
"protein kinase inhibitor",
"cancer treatment",
"akt inhibitor"
] |
{
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
}
|
The molecule is a stabilizing cytochrome oxidase, cholesterol translocation, apoptosis that impacts diabetic heart disease and aging. The molecule is a stabilizing mitochondrial structure and a proton trap for oxidative phosphorylation that impacts tangier disease, non-alcoholic fatty liver disease, and barth syndrome.
|
CCCCCCCCCCCCCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCC(C)C)COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCC
|
[
"Diabetic heart disease",
"Stabilizing cytochrome oxidase",
"Cholesterol translocation",
"Apoptosis",
"Aging",
"Stabilizing mitochondrial structure",
"Tangier disease",
"Non-alcoholic fatty liver disease",
"Barth syndrome",
"Proton trap for oxidative phosphorylation"
] |
{
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
}
|
The molecule is a treatment of disorder.
|
Cc1cc(OCc2ccccc2)c2n[nH]c(Br)c2n1
|
[
"treatment of disorder"
] |
{
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
}
|
The molecule is a cholesterol translocation and a proton trap for oxidative phosphorylation that impacts barth syndrome, diabetic heart disease, and non-alcoholic fatty liver disease. The molecule is a stabilizing cytochrome oxidase, apoptosis, stabilizing mitochondrial structure that impacts tangier disease and aging.
|
CCCCCC/C=C\C=C/CCCCCCCC(=O)OC[C@H](COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCC(C)C)OC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCCCCC
|
[
"Barth syndrome",
"Cholesterol translocation",
"Diabetic heart disease",
"Proton trap for oxidative phosphorylation",
"Non-alcoholic fatty liver disease",
"Stabilizing cytochrome oxidase",
"Apoptosis",
"Stabilizing mitochondrial structure",
"Tangier disease",
"Aging"
] |
{
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
}
|
The molecule is a stabilizing mitochondrial structure, stabilizing cytochrome oxidase, apoptosis that impacts barth syndrome and diabetic heart disease. The molecule is a cholesterol translocation and a proton trap for oxidative phosphorylation that impacts aging, tangier disease, and non-alcoholic fatty liver disease.
|
CCCCC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCC(=O)OC[C@H](COP(=O)(O)OC[C@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCC/C=C\CCCCCC)OC(=O)CCCCCCCCCCCCC
|
[
"Stabilizing mitochondrial structure",
"Stabilizing cytochrome oxidase",
"Barth syndrome",
"Diabetic heart disease",
"Apoptosis",
"Aging",
"Cholesterol translocation",
"Tangier disease",
"Non-alcoholic fatty liver disease",
"Proton trap for oxidative phosphorylation"
] |
{
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
}
|
The molecule is a apoptosis that impacts aging, barth syndrome, diabetic heart disease, and tangier disease. The molecule is a proton trap for oxidative phosphorylation, cholesterol translocation, stabilizing cytochrome oxidase, stabilizing mitochondrial structure that impacts non-alcoholic fatty liver disease.
|
CCCCCCCCCCCCCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCCCCCCCCC)COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCCC(C)C)OC(=O)CCCCCCCCCCCCC(C)C
|
[
"Apoptosis",
"Aging",
"Barth syndrome",
"Diabetic heart disease",
"Tangier disease",
"Proton trap for oxidative phosphorylation",
"Cholesterol translocation",
"Stabilizing cytochrome oxidase",
"Non-alcoholic fatty liver disease",
"Stabilizing mitochondrial structure"
] |
{
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
}
|
The molecule is a stabilizing mitochondrial structure, stabilizing cytochrome oxidase, apoptosis that impacts aging and non-alcoholic fatty liver disease. The molecule is a cholesterol translocation and a proton trap for oxidative phosphorylation that impacts diabetic heart disease, tangier disease, and barth syndrome.
|
CCCCCCCCCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCCCC)COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC
|
[
"Stabilizing mitochondrial structure",
"Aging",
"Stabilizing cytochrome oxidase",
"Non-alcoholic fatty liver disease",
"Apoptosis",
"Cholesterol translocation",
"Diabetic heart disease",
"Tangier disease",
"Barth syndrome",
"Proton trap for oxidative phosphorylation"
] |
{
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
}
|
The molecule is a cholesterol translocation and a proton trap for oxidative phosphorylation that impacts diabetic heart disease, barth syndrome, and non-alcoholic fatty liver disease. The molecule is a stabilizing mitochondrial structure, stabilizing cytochrome oxidase, apoptosis that impacts tangier disease and aging.
|
CCCCCC/C=C\C=C/CCCCCCCC(=O)OC[C@H](COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCC)OC(=O)CCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCCC(C)C
|
[
"Diabetic heart disease",
"Cholesterol translocation",
"Barth syndrome",
"Proton trap for oxidative phosphorylation",
"Non-alcoholic fatty liver disease",
"Stabilizing mitochondrial structure",
"Stabilizing cytochrome oxidase",
"Apoptosis",
"Tangier disease",
"Aging"
] |
{
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
}
|
It impacts cancer treatment.
|
O=C(O)Nc1cc(Oc2ccc([N+](=O)[O-])cn2)c(F)cc1F
|
[
"cancer treatment"
] |
{
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
}
|
The molecule is a cholesterol translocation and a stabilizing cytochrome oxidase that impacts diabetic heart disease, aging, and non-alcoholic fatty liver disease. The molecule is a apoptosis, proton trap for oxidative phosphorylation, stabilizing mitochondrial structure that impacts barth syndrome and tangier disease.
|
CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCCCCC)COP(=O)(O)OC[C@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCC/C=C\C/C=C\C/C=C\CC)OC(=O)CCC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CC
|
[
"Cholesterol translocation",
"Diabetic heart disease",
"Aging",
"Non-alcoholic fatty liver disease",
"Stabilizing cytochrome oxidase",
"Barth syndrome",
"Apoptosis",
"Tangier disease",
"Proton trap for oxidative phosphorylation",
"Stabilizing mitochondrial structure"
] |
{
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
}
|
The molecule is a nutrient that impacts atherosclerosis, breast cancer, cervical cancer, and ulcerative colitis.
|
CC/C=C\C[C@H](O)/C=C/C=C/C=C\C=C/[C@@H](O)[C@H](O)CCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCCc1oc(CCCCC)c(C)c1C)COP(=O)([O-])OCC[N+](C)(C)C
|
[
"Atherosclerosis",
"Breast cancer",
"nutrient",
"Cervical cancer",
"Ulcerative colitis"
] |
{
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
}
|
The molecule is a cholesterol translocation, stabilizing cytochrome oxidase, apoptosis that impacts tangier disease and aging. The molecule is a stabilizing mitochondrial structure and a proton trap for oxidative phosphorylation that impacts diabetic heart disease, non-alcoholic fatty liver disease, and barth syndrome.
|
CCCCCCCCCCCCCCCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCCCCCCCCC(C)C)COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCCCCCC(C)C
|
[
"Cholesterol translocation",
"Stabilizing cytochrome oxidase",
"Tangier disease",
"Aging",
"Apoptosis",
"Diabetic heart disease",
"Non-alcoholic fatty liver disease",
"Stabilizing mitochondrial structure",
"Proton trap for oxidative phosphorylation",
"Barth syndrome"
] |
{
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
}
|
The molecule is a cholesterol translocation, proton trap for oxidative phosphorylation, apoptosis that impacts barth syndrome and aging. The molecule is a stabilizing cytochrome oxidase and a stabilizing mitochondrial structure that impacts diabetic heart disease, non-alcoholic fatty liver disease, and tangier disease.
|
CCCCCCCCCCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCC)COP(=O)(O)OC[C@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCCCCCC(C)C)OC(=O)CCCCCCCCCCCCCCC(C)C
|
[
"Barth syndrome",
"Cholesterol translocation",
"Proton trap for oxidative phosphorylation",
"Aging",
"Apoptosis",
"Diabetic heart disease",
"Non-alcoholic fatty liver disease",
"Tangier disease",
"Stabilizing cytochrome oxidase",
"Stabilizing mitochondrial structure"
] |
{
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
}
|
The molecule is a cholesterol translocation and a stabilizing mitochondrial structure that impacts barth syndrome, tangier disease, and non-alcoholic fatty liver disease. The molecule is a apoptosis, stabilizing cytochrome oxidase, proton trap for oxidative phosphorylation that impacts diabetic heart disease and aging.
|
CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCC(=O)OC[C@H](COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCC/C=C\CCCCCCCC)OC(=O)CCCCCCC/C=C\CCCCCCCC)OC(=O)CCCCCCC/C=C\C/C=C\CCCCC
|
[
"Barth syndrome",
"Cholesterol translocation",
"Tangier disease",
"Stabilizing mitochondrial structure",
"Non-alcoholic fatty liver disease",
"Apoptosis",
"Stabilizing cytochrome oxidase",
"Proton trap for oxidative phosphorylation",
"Diabetic heart disease",
"Aging"
] |
{
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
}
|
The molecule is a nutrient that affects both cervical cancer and breast cancer, and also impacts atherosclerosis and ulcerative colitis.
|
CCCCC/C=C\C/C=C\CCCCCCCCCCCC(=O)OCC(COP(=O)([O-])OCC[N+](C)(C)C)O/C=C\CCCCCCCCCCCCCC
|
[
"Atherosclerosis",
"Cervical cancer",
"nutrient",
"Breast cancer",
"Ulcerative colitis"
] |
{
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
}
|
The molecule is a stabilizing cytochrome oxidase, cholesterol translocation, stabilizing mitochondrial structure that impacts barth syndrome and diabetic heart disease. The molecule is a proton trap for oxidative phosphorylation and a apoptosis that impacts tangier disease, non-alcoholic fatty liver disease, and aging.
|
CCCCCCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCC(C)CC)OC(=O)CCCCCCCCCC(C)C)OC(=O)CCCCCCCCCCCCCCCCCCCCC
|
[
"Barth syndrome",
"Stabilizing cytochrome oxidase",
"Cholesterol translocation",
"Stabilizing mitochondrial structure",
"Diabetic heart disease",
"Tangier disease",
"Proton trap for oxidative phosphorylation",
"Apoptosis",
"Non-alcoholic fatty liver disease",
"Aging"
] |
{
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
}
|
The molecule is a energy source, inflammatory, nutrient that impacts atherosclerosis, metabolic syndrome, and cardiovascular disease. The molecule is a energy storage and thyroxine treatment, and it impacts obesity. The molecule is a membrane stabilizer and a fat storage, with effects on cancer and impacts on pancreatitis.
|
CCCCCCCCCC(=O)OC[C@H](COC(=O)CCCCCCCCCCCC(C)C)OC(=O)CCCCCCCCCCCCCCCCCCC(C)C
|
[
"Atherosclerosis",
"Energy source",
"inflammatory",
"Metabolic syndrome",
"nutrient",
"Cardiovascular disease",
"Thyroxine treatment",
"Obesity",
"Energy storage",
"Pancreatitis",
"Membrane stabilizer",
"Cancer",
"Fat storage"
] |
{
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
}
|
The molecule is a cholesterol translocation, stabilizing cytochrome oxidase, stabilizing mitochondrial structure, apoptosis that impacts non-alcoholic fatty liver disease. The molecule is a proton trap for oxidative phosphorylation that impacts aging, tangier disease, diabetic heart disease, and barth syndrome.
|
CC/C=C\C/C=C\C/C=C\C/C=C\CCCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCCCCCCC)COP(=O)(O)OC[C@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCC/C=C\C/C=C\C/C=C\C/C=C\CCCCC)OC(=O)CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCCC
|
[
"Cholesterol translocation",
"Non-alcoholic fatty liver disease",
"Stabilizing cytochrome oxidase",
"Stabilizing mitochondrial structure",
"Apoptosis",
"Aging",
"Tangier disease",
"Diabetic heart disease",
"Barth syndrome",
"Proton trap for oxidative phosphorylation"
] |
{
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
}
|
The molecule is a nutrient, green, sweet, balsamic, waxy.
|
Cc1ccc(S(=O)(=O)O)cc1.NCC(=O)OCc1ccccc1
|
[
"nutrient",
"green",
"sweet",
"balsamic",
"waxy"
] |
{
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
}
|
The molecule is both a protease inhibitor and a metalloprotease inhibitor.
|
CNCCOc1cccc(-c2ccc(C3CCN(S(=O)(=O)C(C)(C)C(=O)OC)CC3)cc2C)c1
|
[
"protease inhibitor",
"metalloprotease inhibitor"
] |
{
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
}
|
The molecule is a nutrient that impacts both atherosclerosis and pancreatitis. The molecule is a fat storage that impacts cardiovascular disease, thyroxine treatment, and metabolic syndrome.
|
CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCC(=O)OC[C@H](COC(=O)CCCCCCC/C=C\CCCC)OC(=O)CCCCCCCCCCCCCCCCCCCCC
|
[
"nutrient",
"Atherosclerosis",
"Pancreatitis",
"Cardiovascular disease",
"Thyroxine treatment",
"Metabolic syndrome",
"Fat storage"
] |
{
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
}
|
The molecule is a stabilizing mitochondrial structure, cholesterol translocation, stabilizing cytochrome oxidase, proton trap for oxidative phosphorylation that impacts non-alcoholic fatty liver disease. The molecule is a apoptosis that impacts aging, tangier disease, diabetic heart disease, and barth syndrome.
|
CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCCCC(=O)O[C@H](COC(=O)CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCCC)COP(=O)(O)OC[C@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCC/C=C\C/C=C\C/C=C\C/C=C\CC)OC(=O)CCCCCCCCCCCCC
|
[
"Stabilizing mitochondrial structure",
"Cholesterol translocation",
"Stabilizing cytochrome oxidase",
"Proton trap for oxidative phosphorylation",
"Non-alcoholic fatty liver disease",
"Aging",
"Apoptosis",
"Tangier disease",
"Diabetic heart disease",
"Barth syndrome"
] |
{
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
}
|
The molecule is a flavoring agent, herbal, tomato, and lavender. The molecule is a nutrient, green, blueberry, and woody.
|
Cc1occc1SC(C(=O)CC(C)C)C(C)C
|
[
"herbal",
"Flavoring agent",
"tomato",
"lavender",
"nutrient",
"green",
"blueberry",
"woody"
] |
{
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
}
|
It belongs to the chemiluminescent class of molecules.
|
CCOC(=O)c1c(-n2ccnc2)nc(-c2ccccc2)c(N)c1C(=O)OCC
|
[
"chemiluminescent"
] |
{
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
}
|
The molecule is a surfactant, emulsifier, stabilizing mitochondrial structure, membrane stabilizer. The molecule is a stabilizing cytochrome oxidase, a cholesterol translocation, and a energy source, it impacts non-alcoholic fatty liver disease and is smooth. The molecule is a food additive and a nutritional supplement, impacting both tangier disease and aging. The molecule is a apoptosis, energy storage, proton trap for oxidative phosphorylation that impacts diabetic heart disease and barth syndrome.
|
CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCC(=O)OC[C@H](COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCCCCCCCC)OC(=O)CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCCC)OC(=O)CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CC
|
[
"surfactant",
"Emulsifier",
"Stabilizing mitochondrial structure",
"Membrane stabilizer",
"Non-alcoholic fatty liver disease",
"Smooth",
"Stabilizing cytochrome oxidase",
"Cholesterol translocation",
"Energy source",
"Tangier disease",
"Aging",
"food additive",
"Nutritional supplement",
"Apoptosis",
"Energy storage",
"Diabetic heart disease",
"Proton trap for oxidative phosphorylation",
"Barth syndrome"
] |
{
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
}
|
It belongs to the anti viral class of molecules.
|
CC(C)(C)Cc1cc2[nH]ccc(=O)c2s1
|
[
"anti viral"
] |
{
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
}
|
The molecule is a proton trap for oxidative phosphorylation, stabilizing mitochondrial structure, apoptosis that impacts aging and non-alcoholic fatty liver disease. The molecule is a stabilizing cytochrome oxidase and a cholesterol translocation that impacts barth syndrome, diabetic heart disease, and tangier disease.
|
CCCCCCCCCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCC(C)C)COP(=O)(O)OC[C@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCCCCCCCC(C)C)OC(=O)CCCCCCCCCCCCCCCCCCCCC(C)CC
|
[
"Proton trap for oxidative phosphorylation",
"Stabilizing mitochondrial structure",
"Aging",
"Non-alcoholic fatty liver disease",
"Apoptosis",
"Stabilizing cytochrome oxidase",
"Cholesterol translocation",
"Barth syndrome",
"Diabetic heart disease",
"Tangier disease"
] |
{
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
}
|
The molecule is a emulsifier, a surfactant, and a energy source. The molecule is a energy storage and a signalling molecule, impacting both chronic hepatitis and jaundice. It impacts depression, refsum's disease, and alzheimer's disease. The molecule is a membrane stabilizer that affects colorectal cancer by impacting both cirrhosis and chronic diarrhea.
|
CC(CCC[C@@H](C)[C@H]1CC[C@H]2[C@@H]3[C@H](O)C[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3C[C@H](O)[C@]12C)C(=O)O
|
[
"Emulsifier",
"surfactant",
"Energy source",
"Chronic hepatitis",
"Energy storage",
"Jaundice",
"signalling molecule",
"Depression",
"Refsum's disease",
"Alzheimer's Disease",
"Cirrhosis",
"Membrane stabilizer",
"Chronic diarrhea",
"Colorectal cancer"
] |
{
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
}
|
The molecule is a nutrient.
|
COc1ccc(-c2oc3c(OC)cc(OC)c(OC)c3c(=O)c2OC)cc1
|
[
"nutrient"
] |
{
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
}
|
The molecule is a cancer treatment.
|
CC1CN(c2nc(C3CC3)c3c(c2C#N)CC(C)(C)OC3)CCN1C(=O)c1ccco1
|
[
"cancer treatment"
] |
{
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
}
|
The molecule is a stabilizing cytochrome oxidase, apoptosis, stabilizing mitochondrial structure, cholesterol translocation that impacts aging. The molecule is a proton trap for oxidative phosphorylation that impacts non-alcoholic fatty liver disease, tangier disease, barth syndrome, and diabetic heart disease.
|
CCCCCCCCCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCC(C)C)COP(=O)(O)OC[C@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCCCCCC(C)C)OC(=O)CCCCCCCCCCCCCCCCC(C)C
|
[
"Stabilizing cytochrome oxidase",
"Apoptosis",
"Stabilizing mitochondrial structure",
"Aging",
"Cholesterol translocation",
"Non-alcoholic fatty liver disease",
"Tangier disease",
"Barth syndrome",
"Proton trap for oxidative phosphorylation",
"Diabetic heart disease"
] |
{
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
}
|
The molecule is a hbv inhibitor that impacts hepatitis b treatment.
|
O=C(Nc1cccc(C(F)(F)F)c1)c1cc(SNC2CCCCC2)ccc1F
|
[
"hepatitis b treatment",
"hbv inhibitor"
] |
{
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
}
|
The molecule is a anti tumour and belongs to the anti tumor class of molecules, with the characteristic of being anti bacterial agent. The molecule is a anti biotic and belongs to the anti tumor agent class of molecules; it is anti bacterial and anti tumor activity.
|
CCOC(=O)c1cc2cc(NC(=O)c3ccc(C(=O)Nc4ccc5[nH]c(C(=O)OCC)cc5c4)o3)ccc2[nH]1
|
[
"anti tumour",
"anti tumor",
"anti bacterial agent",
"anti bacterial",
"anti biotic",
"anti tumor activity",
"anti tumor agent"
] |
{
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
}
|
It belongs to the anti viral class of molecules.
|
COC(=O)C(OC1CCC(n2cc(C)c(=O)[nH]c2=O)C1)P(=O)(OCOC(=O)C(C)(C)C)OCOC(=O)C(C)(C)C
|
[
"anti viral"
] |
{
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
}
|
The molecule is a nutrient.
|
CCCCCCCCCCCCCCCCCC(=O)OC(CC=C(C)C)/C(C)=C/COc1ccc(CCNC(=O)c2ccccc2)cc1
|
[
"nutrient"
] |
{
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
}
|
The molecule is a hcv treatment and is anti viral.
|
S=C(NCCc1ccccc1)Nc1cccc(OCCCCCc2ccccc2)c1
|
[
"anti viral",
"hcv treatment"
] |
{
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
}
|
The molecule is a anti microbial agent, a anti bacterial, and a anti bacterial agent, it impacts cancer treatment and is anti microbial.
|
COc1cc2ncc(C)c(-c3ccc4c(c3)CN(C(=O)OC(C)(C)C)CC4)c2cc1OC
|
[
"anti microbial",
"anti microbial agent",
"anti bacterial",
"anti bacterial agent",
"cancer treatment"
] |
{
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
}
|
The molecule is a membrane stabilizer, energy source, waste product, nutrient, energy storage.
|
COc1ccccc1C(=O)OC1C(O)C(C)OC(Oc2cc(O)c3c(=O)c(OC4OC(COC5OC(C)C(O)C(O)C5O)C(O)C(O)C4OC4OC(CO)C(O)C(O)C4O)c(-c4ccc(O)cc4)oc3c2)C1O
|
[
"Membrane stabilizer",
"Energy source",
"Waste product",
"nutrient",
"Energy storage"
] |
{
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
}
|
The molecule is a energy source that impacts renal cell carcinoma, inflammatory bowel disease, and breast cancer. It impacts heart failure, celiac disease, diabetes mellitus type 2, and cardiovascular disease.
|
CCCCC=CCC(=O)OC(CC(=O)[O-])C[N+](C)(C)C
|
[
"Energy source",
"Renal cell carcinoma",
"Inflammatory bowel disease",
"Breast cancer",
"Heart failure",
"Celiac disease",
"Diabetes mellitus type 2",
"Cardiovascular disease"
] |
{
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
}
|
The molecule is a platelet aggregation inhibitor.
|
COC(=O)CCC=CC1=CC2CC(OC3CCCCO3)C(C=O)C2C1
|
[
"platelet aggregation inhibitor"
] |
{
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
}
|
The molecule is a fat storage that impacts both cardiovascular disease and pancreatitis. The molecule is a nutrient and thyroxine treatment, impacting both metabolic syndrome and atherosclerosis.
|
CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCCCC(=O)OC[C@@H](COCCCCCCCCCCCCCCCCCC)OC(=O)CCC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CC
|
[
"Cardiovascular disease",
"Fat storage",
"Pancreatitis",
"Thyroxine treatment",
"Metabolic syndrome",
"nutrient",
"Atherosclerosis"
] |
{
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
}
|
The molecule is a prmt5 inhibitor that impacts cancer treatment.
|
CC(=O)N1CCN(c2cc(C(=O)NCC(O)C3Cc4ccc(O)cc4CN3C(=O)O)cc(NC3CCC3)n2)CC1
|
[
"prmt5 inhibitor",
"cancer treatment"
] |
{
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
}
|
The molecule is anti bacterial.
|
O=C(NO)c1cccc(-c2ccc(C#Cc3cccnc3)cc2)n1
|
[
"anti bacterial"
] |
{
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
}
|
The molecule is a nutrient, surfactant, energy source, emulsifier, membrane stabilizer, energy storage.
|
COC(=O)C(OC(=O)c1cc(O)c(O)c(O)c1)C(O)C(O)C(O)C(=O)O
|
[
"nutrient",
"surfactant",
"Energy source",
"Emulsifier",
"Membrane stabilizer",
"Energy storage"
] |
{
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
}
|
The molecule is a liquid crystal.
|
CCCCCC1CCC(C(=O)Oc2ccc(C(=O)O)c(Cl)c2)CC1
|
[
"liquid crystal"
] |
{
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
}
|
The molecule is a proton trap for oxidative phosphorylation and a stabilizing cytochrome oxidase that impacts tangier disease, aging, and non-alcoholic fatty liver disease. The molecule is a stabilizing mitochondrial structure, cholesterol translocation, apoptosis that impacts diabetic heart disease and barth syndrome.
|
CCCCC/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)OC[C@H](COP(=O)(O)OC[C@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCC/C=C\C/C=C\CCCCC)OC(=O)CCCCCCCCC/C=C\C/C=C\CCCCC)OC(=O)CCCCCCC/C=C\C/C=C\CCCCC
|
[
"Tangier disease",
"Aging",
"Non-alcoholic fatty liver disease",
"Proton trap for oxidative phosphorylation",
"Stabilizing cytochrome oxidase",
"Stabilizing mitochondrial structure",
"Cholesterol translocation",
"Diabetic heart disease",
"Apoptosis",
"Barth syndrome"
] |
{
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
}
|
The molecule is a apoptosis and smooth, impacting both diabetic heart disease and barth syndrome. The molecule is a stabilizing cytochrome oxidase, cholesterol translocation, proton trap for oxidative phosphorylation, nutritional supplement that impacts aging. The molecule is a membrane stabilizer and a energy source, impacting both tangier disease and non-alcoholic fatty liver disease. The molecule is a food additive, surfactant, energy storage, stabilizing mitochondrial structure, emulsifier.
|
CCC(C)CCCCCCCCC(=O)OC[C@H](COP(=O)(O)OC[C@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCCCCCCCCCC(C)C)OC(=O)CCCCCCCCCCCCC(C)C)OC(=O)CCCCCCCCCCC(C)C
|
[
"Smooth",
"Diabetic heart disease",
"Apoptosis",
"Barth syndrome",
"Stabilizing cytochrome oxidase",
"Aging",
"Cholesterol translocation",
"Proton trap for oxidative phosphorylation",
"Nutritional supplement",
"Tangier disease",
"Non-alcoholic fatty liver disease",
"Membrane stabilizer",
"Energy source",
"food additive",
"surfactant",
"Energy storage",
"Stabilizing mitochondrial structure",
"Emulsifier"
] |
{
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
}
|
The molecule is a nutrient that impacts diabetes mellitus type 2, alzheimer's disease, non-alcoholic fatty liver disease, and parkinson's disease.
|
CC/C=C\C/C=C\C/C=C\C/C=C\CCCCCCC(=O)O[C@H](CO/C=C\CCCCCCCCCCCCCCCC)COP(=O)(O)OCCN
|
[
"Diabetes mellitus type 2",
"nutrient",
"Alzheimer's Disease",
"Non-alcoholic fatty liver disease",
"Parkinson's disease"
] |
{
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
}
|
The molecule is a nutrient that impacts both erythema and edema.
|
CC1=CCC2C(C)(C)C(=O)CCC2(C)C1COc1ccc2ccc(=O)oc2c1
|
[
"nutrient",
"Erythema",
"Edema"
] |
{
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
}
|
The molecule is a cholesterol translocation, proton trap for oxidative phosphorylation, stabilizing cytochrome oxidase that impacts tangier disease and diabetic heart disease. The molecule is a apoptosis and a stabilizing mitochondrial structure that impacts non-alcoholic fatty liver disease, aging, and barth syndrome.
|
CCCCC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCC(=O)OC[C@H](COP(=O)(O)OC[C@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCCCC)OC(=O)CCCCCCCCC/C=C\C/C=C\CCCCC)OC(=O)CCCCCCCCCCCCCCC
|
[
"Tangier disease",
"Cholesterol translocation",
"Proton trap for oxidative phosphorylation",
"Stabilizing cytochrome oxidase",
"Diabetic heart disease",
"Apoptosis",
"Non-alcoholic fatty liver disease",
"Aging",
"Barth syndrome",
"Stabilizing mitochondrial structure"
] |
{
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
}
|
The molecule is a ferroelectric and belongs to the liquid crystal class of molecules.
|
C=CC(=O)OCCCCCCCCCCCCOC1(CC(C)CC)C=CC(c2ccccc2)=CC1
|
[
"liquid crystal",
"ferroelectric"
] |
{
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
}
|
The molecule is a anti apoptotic.
|
O=[N+]([O-])c1cc(S(=O)(=O)Nc2ncnc3cc(N4CCN(Cc5ccccc5-c5ccc(Cl)cc5)CC4)ccc23)ccc1NC(CCN1CCC1)CSc1ccccc1
|
[
"anti apoptotic"
] |
{
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
}
|
The molecule is a fat storage and a inflammatory that impacts atherosclerosis, obesity, metabolic syndrome, and cardiovascular disease. The molecule is a nutrient that impacts both thyroxine treatment and pancreatitis. The molecule is a energy storage, membrane stabilizer, energy source with an effect on cancer.
|
CCCCCCCCCCCCCCCC(=O)OC[C@H](COC(=O)CCCCCCCCCCCCCCCCC(C)CC)OC(=O)CCCCCCCCCCCC
|
[
"Atherosclerosis",
"Fat storage",
"Obesity",
"Metabolic syndrome",
"inflammatory",
"Cardiovascular disease",
"nutrient",
"Thyroxine treatment",
"Pancreatitis",
"Energy storage",
"Membrane stabilizer",
"Cancer",
"Energy source"
] |
{
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
}
|
The molecule is a stabilizing cytochrome oxidase and a stabilizing mitochondrial structure that impacts diabetic heart disease, barth syndrome, and tangier disease. The molecule is a apoptosis, cholesterol translocation, proton trap for oxidative phosphorylation that impacts aging and non-alcoholic fatty liver disease.
|
CCCCCCCCCCCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCCCC(C)C)COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCCC
|
[
"Diabetic heart disease",
"Barth syndrome",
"Tangier disease",
"Stabilizing cytochrome oxidase",
"Stabilizing mitochondrial structure",
"Apoptosis",
"Aging",
"Cholesterol translocation",
"Non-alcoholic fatty liver disease",
"Proton trap for oxidative phosphorylation"
] |
{
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
}
|
The molecule is anesthetic.
|
COc1ccc2c(c1)oc(=O)c1c3ccc(O)cc3oc21
|
[
"anesthetic"
] |
{
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
}
|
It impacts stomach cancer, alzheimer's disease, parkinson's disease, and cardiovascular disease. It has an effect on colorectal cancer, and impacts breast cancer, seizure, and diabetes mellitus.
|
CCCCC/C=C\C/C=C\C/C=C\C=C\C(=O)CCCC(=O)OC[C@H](COP(=O)(O)O[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@H](O)[C@H]1O)OC(=O)CCCC/C=C\C/C=C\C/C=C\CCCCC
|
[
"Stomach cancer",
"Alzheimer's Disease",
"Parkinson's disease",
"Cardiovascular disease",
"Colorectal cancer",
"Breast cancer",
"Seizure",
"Diabetes mellitus"
] |
{
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
}
|
It impacts cardiovascular disease, alzheimer's disease, diabetes mellitus, and seizure. It influences both stomach cancer and colorectal cancer, as well as affecting parkinson's disease and breast cancer.
|
CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCCCC(=O)O[C@H](COC(=O)CCC/C=C\C/C=C\C=C\[C@H](O)C/C=C\CCCCC)COP(=O)(O)O[C@H]1C(O)C(O)C(O)[C@@H](OP(=O)(O)O)C1O
|
[
"Cardiovascular disease",
"Alzheimer's Disease",
"Diabetes mellitus",
"Seizure",
"Parkinson's disease",
"Stomach cancer",
"Breast cancer",
"Colorectal cancer"
] |
{
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
}
|
The molecule is a surfactant and a membrane stabilizer, impacting both barth syndrome and non-alcoholic fatty liver disease. The molecule is a proton trap for oxidative phosphorylation, stabilizing cytochrome oxidase, stabilizing mitochondrial structure, cholesterol translocation that impacts diabetic heart disease. The molecule is a energy source and a nutritional supplement, it impacts aging, and is smooth. The molecule is a apoptosis, energy storage, food additive, emulsifier that impacts tangier disease.
|
CCC(C)CCCCCCCCCCC(=O)OC[C@H](COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCC(C)C)OC(=O)CCCCCCCCCC(C)C)OC(=O)CCCCCCCCCCCCCCCCCCCCC(C)C
|
[
"Barth syndrome",
"surfactant",
"Membrane stabilizer",
"Non-alcoholic fatty liver disease",
"Proton trap for oxidative phosphorylation",
"Stabilizing cytochrome oxidase",
"Diabetic heart disease",
"Stabilizing mitochondrial structure",
"Cholesterol translocation",
"Energy source",
"Smooth",
"Nutritional supplement",
"Aging",
"Tangier disease",
"Apoptosis",
"Energy storage",
"food additive",
"Emulsifier"
] |
{
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
}
|
The molecule is a proteasome inhibitor.
|
O=C(O)C(O)(Cl)C(O)C(O)CO
|
[
"proteasome inhibitor"
] |
{
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
}
|
The molecule is a nutrient.
|
CCCCC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCC(=O)OC[C@H](COP(=O)(O)OC[C@H](N)C(=O)O)OC(=O)CCC/C=C\C/C=C\C/C=C\CC1OC1CCCCC
|
[
"nutrient"
] |
{
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
}
|
The molecule is sour, malt, peach, and ethereal. The molecule is a flavor that impacts hepatic encephalopathy and is chocolate, fatty, and aldehydic.
|
CCCCCCCCCCCCCC/C=C/[C@@H](O)[C@H](COP(=O)([O-])OCC[N+](C)(C)C)NC(=O)CCCCCCCCCCCCCCC
|
[
"sour",
"malt",
"peach",
"ethereal",
"chocolate",
"fatty",
"Hepatic encephalopathy",
"flavor",
"aldehydic"
] |
{
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
}
|
The molecule is a nutrient that impacts both atherosclerosis and metabolic syndrome. The molecule is a thyroxine treatment and a fat storage, impacting both pancreatitis and cardiovascular disease.
|
CCCCC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCC(=O)O[C@H](COC(=O)CCCCCCC/C=C\C/C=C\CCCCC)COC(=O)CCCCCCCCCCCCCCCCCCCCC
|
[
"Atherosclerosis",
"Metabolic syndrome",
"nutrient",
"Pancreatitis",
"Thyroxine treatment",
"Cardiovascular disease",
"Fat storage"
] |
{
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
}
|
The molecule is a nutrient that impacts alzheimer's disease, diabetes mellitus type 2, parkinson's disease, and non-alcoholic fatty liver disease.
|
CCCCC/C=C\C/C=C\C/C=C\CCCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCC/C=C\C/C=C\C/C=C\C=C\C(=O)CCCCC
|
[
"nutrient",
"Alzheimer's Disease",
"Diabetes mellitus type 2",
"Parkinson's disease",
"Non-alcoholic fatty liver disease"
] |
{
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
}
|
The molecule is a fat storage, thyroxine treatment, membrane stabilizer, energy source, energy storage with an effect on cancer. The molecule is a inflammatory that impacts both obesity and atherosclerosis. The molecule is a nutrient that impacts pancreatitis, cardiovascular disease, and metabolic syndrome.
|
CCCCCCCCCCCCCCCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCCCCCCCCCC(C)C)OC(=O)CCCCCCC
|
[
"Cancer",
"Fat storage",
"Thyroxine treatment",
"Membrane stabilizer",
"Energy source",
"Energy storage",
"Obesity",
"Atherosclerosis",
"inflammatory",
"Pancreatitis",
"Cardiovascular disease",
"nutrient",
"Metabolic syndrome"
] |
{
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
}
|
The molecule is a proton trap for oxidative phosphorylation that impacts tangier disease, diabetic heart disease, barth syndrome, and aging. The molecule is a stabilizing mitochondrial structure, apoptosis, stabilizing cytochrome oxidase, cholesterol translocation that impacts non-alcoholic fatty liver disease.
|
CCCCC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCC(=O)O[C@H](COC(=O)CCCCCCCCCCCCC)COP(=O)(O)OC[C@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCC/C=C\CCCCCCCC)OC(=O)CCCCCCCCCCCCCCC
|
[
"Tangier disease",
"Proton trap for oxidative phosphorylation",
"Diabetic heart disease",
"Barth syndrome",
"Aging",
"Stabilizing mitochondrial structure",
"Apoptosis",
"Non-alcoholic fatty liver disease",
"Stabilizing cytochrome oxidase",
"Cholesterol translocation"
] |
{
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
}
|
The molecule is a stabilizing mitochondrial structure, proton trap for oxidative phosphorylation, apoptosis that impacts diabetic heart disease and non-alcoholic fatty liver disease. The molecule is a stabilizing cytochrome oxidase and a cholesterol translocation that impacts aging, tangier disease, and barth syndrome.
|
CCCCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCC)OC(=O)CCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCCCCCCCC(C)C
|
[
"Stabilizing mitochondrial structure",
"Proton trap for oxidative phosphorylation",
"Diabetic heart disease",
"Apoptosis",
"Non-alcoholic fatty liver disease",
"Aging",
"Tangier disease",
"Barth syndrome",
"Stabilizing cytochrome oxidase",
"Cholesterol translocation"
] |
{
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
}
|
It impacts pain treatment.
|
COc1cccc(Nc2ncnc3c2CCN(c2cc(C(F)(F)F)ccn2)C3)c1
|
[
"pain treatment"
] |
{
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
}
|
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.